United States (USA) IVF (in-vitro fertilization) Market Overview, 2029

The in vitro preparation (IVF) market in the US is a unique scene molded by headways in innovation, segment patterns, and administrative variables. IVF, a regenerative innovation used to consider undeveloped organisms outside the body, has become progressively well known among couples confronting Infertilitychallenges. The market is driven by a blend of variables including mechanical developments, increasing Infertility rates, and expanded mindfulness about helped regenerative methods. Innovative progressions have essentially further developed the achievement paces of IVF techniques. Methods, for example, intracytoplasmic sperm infusion (ICSI), preimplantation hereditary testing (PGT), and undeveloped organism vitrification have added to higher achievement rates and decreased hazard of hereditary anomalies. Also, advancements in observing frameworks have upgraded the checking of undeveloped organism improvement, further developing results. Segment patterns, including deferred childbearing and way of life changes, have prompted an expansion in Infertility rates, further driving interest for IVF administrations. In spite of varieties in state guidelines, the American Culture for Conceptive Medication (ASRM) gives rules and norms to fruitfulness facilities, guaranteeing nature of care across the business. In the US in vitro fertilization (IVF) market, key players include the American Society for Reproductive Medicine (ASRM) for setting standards, guidelines, and education. Various fertility clinics and centers, such as Shady Grove Fertility, Columbia University Fertility Center, and Mayo Clinic Fertility Clinic, offer IVF services across the country. Medical device and biotechnology companies like Cook Medical, Thermo Fisher Scientific, and Merck KGaA provide essential equipment, consumables, and genetic testing solutions. Pharmaceutical giants like Merck & Co. and Ferring Pharmaceuticals produce fertility medications necessary for IVF protocols. According to the research report "US Infertility Treatment Market Overview, 2029," published by Bonafide Research, the US infertility treatment market is anticipated to grow at more than 7.21% CAGR from 2024 to 2029. The In Vitro Fertility (IVF) market in the US is ready for critical development, energized by a few key variables. One significant main thrust is the rising acknowledgment and standardization of helped regenerative innovations (Workmanship) among couples battling with infertility. As cultural perspectives shift and mindfulness spreads in regards to infertility medicines, more people and couples are looking for IVF as a practical answer for imagine. Progressions in innovation and procedures inside the IVF field are likewise adding to advertise extension. Developments like preimplantation hereditary testing (PGT), time-pass imaging frameworks, and further developed cryopreservation techniques have improved achievement rates and diminished the gamble of hereditary anomalies, accordingly drawing in additional patients to seek after IVF medicines. The extending extent of IVF administrations and the accessibility of thorough ripeness centers offering a scope of medicines under one rooftop are driving patient comfort and fulfillment. These facilities frequently give customized treatment plans, guiding administrations, and comprehensive consideration, taking care of the assorted requirements of people and couples going through richness treatment. The rising pattern of postponed childbearing among ladies because of elements like profession pursuits, instructive accomplishment, and monetary dependability is one more huge development driver for the IVF market. As additional ladies pick to have youngsters further down the road, the interest for fruitfulness medicines, including IVF, is supposed to rise. Positive repayment strategies and protection inclusion for IVF methodology in certain states are eliminating monetary obstructions for patients, making treatment more open and reasonable. Continuous innovative work drives pointed toward further developing IVF results, for example, the investigation of new ripeness drugs, high level undeveloped organism determination calculations, and harmless incipient organism evaluation procedures, are expected to add to the extension of the IVF market in the US.

A fresh non-donor in-vitro fertilization cycle involves the stimulation of the ovaries using fertility medications to produce multiple eggs. These eggs are then retrieved transvaginally under ultrasound guidance. Following retrieval, the eggs are fertilized with sperm in a laboratory dish, and resulting embryos are cultured for a few days. Typically, one or more embryos are transferred into the uterus, and any remaining viable embryos can be cryopreserved for future use. This cycle offers the advantage of immediate embryo transfer, potentially increasing the chance of successful implantation in US. In US a frozen non-donor IVF cycle, the process is similar to a fresh cycle until the embryo transfer stage. Instead of transferring embryos immediately, any viable embryos are cryopreserved using a process called vitrification. These frozen embryos can then be thawed and transferred into the uterus at a later time, allowing for more flexibility in scheduling and potentially higher success rates as the uterus can be prepared optimally for implantation. In a frozen donor in-vitro fertilization cycle, the process involves using donated eggs from a third-party donor. The donor eggs are fertilized with sperm, and resulting embryos are cryopreserved. The recipient's uterus is prepared through hormonal medications to receive the embryos, and then the frozen embryos are thawed and transferred. This cycle offers the advantage of having access to a larger pool of donor eggs and the flexibility of scheduling the embryo transfer. A fresh donor in-vitro fertilization cycle involves using donated eggs from a third-party donor, but unlike the frozen donor cycle, the eggs are fertilized immediately after retrieval, and resulting embryos are transferred into the recipient's uterus within the same cycle. This cycle can be advantageous in cases where fresh embryos are preferred, and it may offer slightly higher success rates compared to frozen donor cycles. In this method, mature eggs retrieved from the woman's ovaries are combined with sperm in a laboratory dish. The sperm naturally fertilizes the eggs, leading to the formation of embryos. After a few days of monitoring embryo development, one or more healthy embryos are transferred to the woman's uterus, with any remaining embryos potentially being frozen for future use. This method is suitable for couples with mild to moderate fertility issues. In-vitro fertilization with ICSI (Intracytoplasmic Sperm Injection): This technique is used when male infertility factors are present. With ICSI, a single sperm is directly injected into each mature egg to facilitate fertilization. It is beneficial for couples dealing with sperm abnormalities, low sperm count, or issues with sperm motility. In US, In-vitro fertilization with ICSI has become increasingly popular in the U.S. due to its high success rates in overcoming male infertility. For women who cannot produce viable eggs due to age-related decline, genetic disorders, or other medical reasons, IVF with donor eggs offers a solution. In this procedure, eggs from a donor are fertilized with the partner's or donor's sperm through conventional IVF or ICSI. The resulting embryos are then transferred to the recipient's uterus, allowing them to carry the pregnancy to term. This option provides hope for women who have exhausted other fertility treatments. In addition to these main types, the U.S. IVF market also offers variations and advancements in techniques, such as preimplantation genetic testing (PGT) to screen embryos for genetic abnormalities before transfer, and egg freezing for fertility preservation. These options cater to diverse fertility needs and preferences, making IVF a versatile and effective solution for many individuals and couples facing infertility. Fertility clinics specialize in diagnosing and treating infertility issues in individuals and couples. These clinics offer a wide range of services, including fertility testing, ovulation induction, intrauterine insemination (IUI), in-vitro fertilization, and other assisted reproductive technologies. Fertility clinics typically have experienced reproductive endocrinologists, embryologists, and fertility nurses on staff to provide comprehensive care. They also offer counseling and support services to help patients navigate the emotional aspects of infertility treatment. Many hospitals and surgical centers in the US also offer in-vitro fertilization and other reproductive services as part of their broader healthcare offerings. These facilities may have dedicated reproductive medicine departments or work in collaboration with fertility specialists to provide comprehensive care. Hospitals and surgical centers are equipped to handle more complex cases, such as fertility preservation for cancer patients, reproductive surgeries, and advanced fertility treatments like preimplantation genetic testing and embryo biopsy. Cryobanks play a crucial role in the storage and preservation of reproductive materials, including sperm, and embryos,eggs. These facilities adhere to strict regulations to ensure the safety and integrity of stored specimens. Cryobanks provide services such as sperm banking for individuals undergoing cancer treatment, egg freezing for women who wish to preserve their fertility, and embryo storage for patients undergoing in-vitro fertilization. They also facilitate the donation and distribution of reproductive materials for fertility treatments and research purposes. Research institutes contribute to advancements in reproductive medicine by conducting studies on infertility, embryology, and reproductive technologies. These institutions often collaborate with fertility clinics, hospitals, and academic centers to explore new treatments, improve existing protocols, and address unanswered questions in the field of reproductive health. Research institutes may also house fertility laboratories where scientists study gamete and embryo development, genetics, and epigenetics to enhance our understanding of human reproduction.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029 Aspects covered in this report • IVF market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By cycle • Fresh Non-donor IVF Cycle • Frozen Non-donor IVF Cycle • Frozen donor IVF Cycle • Fresh donor IVF Cycle

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

By Conventional IVF • Conventional IVF • IVF with ICSI (Instracytoplasmic Sperm Injection) • IVF With Donor Eggs • other By End user • Fertility Clinics • Hospital & Surgical Centers • Cryobanks • Research institute The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.